ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO845

Screening Fabry Disease in Women Combining Enzyme Activity with Lyso-GL3: Results of a Brazilian Study

Session Information

Category: Women's Health and Kidney Diseases

  • 2200 Women's Health and Kidney Diseases


  • Silva, Cassiano Augusto, Universidade Estadual Paulista Julio de Mesquita Filho, Botucatu, SP, Brazil
  • Barreto, Fellype, Universidade Federal do Parana, Curitiba, PR, Brazil
  • Vieira Neto, Osvaldo Merege, Universidade de Sao Paulo, Ribeirão Preto, SP, Brazil
  • Lucca, Leandro Jr., Universidade de Sao Paulo, Ribeirão Preto, SP, Brazil
  • Vieira, Fernando Ant?nio Freitas, Clirenal, Caratinga, MG, Brazil
  • Gueiros, Ana Paula, Instituto de Medicina Integral Professor Fernando Figueira, Recife, PE, Brazil
  • Boger, Marta Vaz Dias de Souza, Metta Saúde Clínica do Rim, Foz do Iguaçu, PR, Brazil
  • Silva, Artur Quintiliano, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil
  • Guedes, Felipe Leite, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil
  • Israel, Karla Cristina Petruccelli, Universidade Federal do Amazonas, Manaus, AM, Brazil
  • Moreno Gordon, Gina, Grupo Instituto do Rim do Paraná, Curitiba, PR, Brazil
  • Souza, Eduarda M S M M, Sanofi-Genzyme, São Paulo, SP, Brazil
  • Veloso, Valeria, Universidade Federal de Goias, Goiania, GO, Brazil
  • Sevignani, Gabriela, Fundacao Pro-Rim, Joinville, SC, Brazil
  • Barretto, Carolina, Santa Casa de Misericordia de Itabuna, Itabuna, Bahia, Brazil
  • Pascotto, Roberta Correa, Santa Casa de Maringa, Maringa, PR, Brazil
  • Ennes, Gelzie Sorrentino, Centro de nefrologia de Nova Friburgo, Nova Friburgo, RJ, Brazil
  • Ribeiro, Márcia Gonçalves, DLE, Rio de Janeiro, RJ, Brazil
  • Modelli de Andrade, Luis Gustavo, Universidade Estadual Paulista Julio de Mesquita Filho, Botucatu, SP, Brazil

Fabry disease (FD) is a rare X-linked lysosomal storage disease that can affect multiple organs, including the kidneys. The main objective of this study was to evaluate the effectiveness of a combination of α-GAL enzyme activity and plasma levels of lyso-GL3 for screening FD in women with chronic kidney disease (CKD).


Women with CKD, stages 3 to 5, in regular nephrological follow-up were selected from renal centers in all regions of Brazil. Exclusion criteria: under 18 years old and known diagnosis of FD. Patients underwent biochemical analysis of α-GAL enzyme activity and plasma levels of lyso-GL3. GLA gene sequencing was performed if α-GAL enzyme activity was below and/or lyso-GL3 levels were above the reference range. Sensitivity and specificity analyzes were performed to evaluate the performance of the combined biochemical approach for the diagnosis of FD.


From October 2020 to December 2022 1,647 collections were carried out. Low α-GAL activity was found in 44 (2.6%) of the cases and increased lyso-GL3 was found in 101 (6.1%) of the cases. The mean age was 53 [42 – 64] years. All cases of low α-GAL and/or increased lyso-GL3 were submitted to genetic analysis, and 6 positive cases were found. As for genetic variants, four patients have R118C, one A143T and other with T430G, all considered variants of uncertain significance (VUS). The sensitivity and specificity of α-GAL reduction for the detection of FD was 83.3% and 97.6%, respectively. As for the increase in lyso-GL3, the values were 16.6% and 93.9%, respectively. There were no cases that presented a concomitant increase in lyso-GL3 and a reduction in enzymatic activity.


Preliminary results suggest that the combination of α-GAL enzymatic activity with lyso-GL3 measurement may be a good alternative for screening FD in women with CKD. A thorough medical evaluation is required to determine the pathogenicity of variants in these patients.


  • Commercial Support – Sanofi-Genzyme